Floatz logo

Epirubicin

Malignant Pleural Disease

Memorial Sloan Kettering Cancer CenterPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Malignant Pleural Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Benadryl
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Icasp9M28Z T Cell Infusions
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →